All these findings imply that hnRNPA2B1 could be a novel tumor target and a biomarker for monitoring treatment response and evaluating prognosis; however, to the best of our knowledge, no imaging agents based on hnRNPA2B1 antibody have been reported to date. Here, HNRNPA2B1 is linked to neoplasm.